4M Therapeutics
Skillman, New Jersey

4M Therapeutics has a small molecule pipeline targeting a pathway disrupted in bipolar disorder, Alzheimer's disease, and other conditions. Lithium helps control this pathway, but only at high doses with too many side effects. New data show our candidates are 10,000 times more potent than lithium, with potentially better safety. We are 18 to 24 months from our first clinical trial. Our three pipeline products reflect extensive laboratory research on living human brain cells. Our unique expertise at 4M Therapeutics provides a scientific platform for new breakthroughs in treating neurological and psychiatric disorders.

http://www.4mtx.net
Pablo Lapuerta | pablo@4mtx.net

Advanced Scanners
Austin, Texas

Advanced Scanners' builds an optical scanner that tracks anatomic motion during surgery and updates (corrects) surgical navigation, robotic, and AR/VR platforms so they present accurate information to the surgeon throughout a procedure. We are working with market-leading companies toward commercial solutions for cranial, spine, and orthopedic procedures. We are raising a Series A round and looking for institutional investors to co-invest alongside multiple strategic partners.

https://www.advancedscanners.com
Jeff Levine | jeffl@advancedscanners.com

Autonomize
Austin, Texas

Autonomize is a human-centered AI company that is democratizing access to data to power health outcomes. The Autonomize Health Data platform automates deep insights from heterogeneous, multi-structured clinical and non-clinical datasets (like EHR, Claims, Patient Reported Outcomes, Research and biomedical literature) to augment Healthcare & Life Sciences organizations to make critical decisions with speed and accuracy. Delivered as a secure, cloud-based, scalable platform, we support a wide range of use cases from accelerating clinical trials, real-world evidence (RWE) studies, to using precision analytics and personalization to support care delivery and care management.

https://autonomize.ai
Ganesh Padmanabhan | ganesh@autonomize.ai

Bairitone Health
Houston, Texas

Bairitone is developing an innovative approach to identify anatomical sites contributing to snoring and sleep apnea. We are making a wearable to help people sleep better and healthier. The SOMNAR platform detects tissue-borne sounds, recognizes their association with normal breathing, snore, or apnea, and identifies the location and type of obstruction in the upper airway. The technology enables the anatomical diagnosis of snoring and obstructive sleep apnea (OSA) in the home environment, thereby making it more accessible and solving a significant diagnostic bottleneck in the sleep care pathway.

http://www.bairitone.com
Meagan Pitcher | meagan@bairitone.com

bEHR Health Systems
New Orleans, Louisiana

bEHR delivers medical, lifestyle, and social solutions to health for African Americans. Our mission is to maximize Black health, using health equity best practices, and the latest innovations in anti-aging and longevity. Our vision is to make health part of Black culture– placing it at the core of how we live, work, play, and celebrate in the Black Community.

http://behrhs.com
Kwame Terra | kwameterra@behrhs.com

BioPact Cellular Transport
Austin, Texas

BioPact is developing a next generation transfection technology (MGMR) as an alternative to viral vectors. MGMR penetrates cells without compromising membrane integrity or inducing cytotoxicity, and it can transport both small and large molecular cargos at a fraction of the time and cost. BioPact has over 120 issued patents. This flexible system can be applied ex-vivo or in vitro models and is both scalable and quantifiable. BioPact is working with the DoD to load and deliver monoclonal antibody encoded plasmid DNA in and with other biopharma partners delivering various biomolecules. BioPact is led by an ex-VP R&D, Plastics, Dow Chemical.

http://biopactct.com
Kurt Swogger | kswogger@molecularrebar.com

Bloom Standard
St. Paul, Minnesota

Bloom Standard is the first self-driving ultrasound platform specifically designed to earlier identify babies and children with heart and lung conditions in primary care and underserved medical settings. The EVA (Echo Virtual Automation) device is built on a RAPID (Rapid Autonomous Pediatric Imaging Diagnostic) protocol for primary care and public health deployment of ultrasound screening utilizing clinical decision support algorithms and non-radiating chip-based ultrasound sensors to reduce deaths and poor outcomes associated with late diagnosis, missed or misdiagnosis.

https://www.bloomstandard.com/
Annamarie Saarinen | am@bloomstandard.com

Bondwell Technologies
College Station, Texas

Antibody-based drugs are highly effective, but extremely expensive to produce and require large doses to be clinically effective. There is a tremendous need to improve process efficiency and reduce manufacturing costs, ultimately allowing more patients to access affordable treatments. Our membrane-based antibody purification system increases production efficiency 10-fold while reducing the equipment footprint and eliminating the need for column cleaning procedures. This product is designed to disrupt the $1.1 Billion biomanufacturing market.

http://bondwelltech.com
David Howell | dhowell@bondwelltech.com

Cellula Therapeutics
Houston, Texas

Cellula is developing a game changing CAR-T platform by overexpressing a secreted bispecific ADAxCD3 protein and a membrane CD26 (designated as MRCAR). ADAxCD3 coverts adenosine, an immunosuppressive metabolite, to inosine as an alternative energy resource for CAR-T persistence, while CD26 endows CAR-T with elevated homing capacity and cytotoxicity. MRCAR is a differentiated CAR-T technology with a greater potential to cure solid tumors.

http://google.com
Xiaotong Song | xsong@tamu.edu

Chrysalis BioTherapeutics
Galveston, Texas

Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of treatments for serious respiratory disorders and acute radiation exposure. The lead product, TP508 (Rusalatide acetate, Chrysalin™) is a first-in-class regenerative peptide in development: 1) for treatment of acute respiratory distress syndrome caused by COVID-19 and non-COVID-19 ARDS; and 2) as a nuclear countermeasure to mitigate effects of radiation exposure in collaboration with BARDA and NIAID. In 2012, the we acquired ownership of TP508 clinical and non-clinical safety & efficacy data, an inventory of cGMP TP508, & licenses to the TP508 patent portfolio.

http://www.chrysbio.com
Darnell Carney | dcarney@chrysbio.com

CorInnova
Houston, Texas

CorInnova is developing a non-blood contacting biventricular cardiac assist device for the treatment of acute heart failure that would eliminate many adverse events associated with existing cardiac assist devices due to blood contact. The device, initially for the fast-growing short-term cardiac assist market (up to 7 days' use), will expand addressable market to $6B+. The self-expanding, pneumatically driven device consists of collapsible thin-film polyurethane chambers with a nitinol wire frame that deploys within the pericardial sac and surrounds both ventricles. The device gently compresses the heart to increase output using a pneumatic driver that operates in synchrony with the heartbeat.

http://www.corinnova.com
Boris Leschinsky | boris.leschinsky@corinnova.com

Cx Precision Medicine
Fort Worth, Texas

Cx Precision Medicine is devoted to changing expectations for patients suffering from Alzheimers and other neurodegenerative diseases by developing tools to accelerate diagnosis, facilitate personalized therapeutic treatment and improve patient outcomes. Our first product, a blood based screening test to rule-out Alzheimers Disease will be ready to launch in 2023. A rule-out test for Parkinson's Disease follows as do products to subtype these diseases to determine therapeutics likely to be effective for particular patients.

http://www.cxprecisionm.com
Danguole Altman | daltman@cxprecisionm.com

DECISIO Health
Houston, Texas

DECISIO is the leading critical-condition decision support company with deep health care and information technology expertise. We work alongside clinicians and hospital executives to develop products that empower teams to improve patient outcomes and patient safety. Our products help optimize clinical workflows to identify at-risk patients early, reduce hospital complications, and efficiently comply with established clinical guidelines. Additionally, our products can help increase revenue by identifying missed documentation opportunities for the provided care.

http://decisiohealth.com
Binod Shrestha | binod@decisiohealth.com

EMPIRI
Houston, Texas

EMPIRI is an early-stage, CLIA certified, biotechnology platform company currently focused on precision oncology. Our proprietary 3D tissue culture method (E-slice) enables personalized drug response measurements from intact patient tissues. E-slice has been clinically validated to accurately predict individual cancer patient responses to chemotherapies, targeted therapies and immunotherapies. We are initiating retrospective and prospective trials with NCI R01 grant funds. We are also automating this game changing technology for personalized cancer diagnostics to expand its usage in preclinical and clinical settings. Oncology is just the beginning. Our technology has application in other areas such as neurology and toxicology.

http://www.empiricancer.com
Dave Gallup | dgallup@empiricancer.com

FGH Biotech
Houston, Texas

FGH Biotech, Inc. is a pre-clinical stage biotechnology company, developing first-in-class portfolio of small molecule drugs, fatostatins, that regulate pathologic fat production, a primary source of energy for a variety of cancers. The Company has demonstrated animal in-vivo efficacy in cancer models, synthesized commercial quantities of drug substance, optimized drug product, scheduled GLP toxicology studies, targeting first in human studies in mid 2023. Clinical indication targets are metastatic uveal melanoma, castration resistant prostate cancer and triple negative breast cancer.

http://www.fghbiotech.com
Bill Burns | bburns@fghbiotech.com

Geneial
Missouri City, Texas

We create revenue for data owners via a private channel for data liquidity, and in doing so decrease the cost of research and development for healthcare and biopharma. Over 400M individuals suffer from a rare disease, yet only 5% of these have an available treatment – this is largely because data is highly fragmented across silos, which impedes the progress of research and development. Accessing data across silos is necessary, but data privacy and ownership concerns prevent widespread data exchange. To solve this, we are building a decentralized platform for granular data exchange that safeguards individual privacy and protects data ownership.

http://www.geneial.com
Adam Hansen | adam@geneial.com

Grapheton
Carlsbad, California

Grapheton is replacing the metals used in bioelectronic implants with much safer, longer-lasting carbon materials. Metals are used today more than any other material in these implants, but they are foreign to the body, corrode, and have limited measurement capabilities. Grapheton uses "bio-friendly" carbon-based materials to create highly durable implants that measure a broad range of biochemical and electrical responses. We believe the next generation of implants in this $30 billion market will use our carbon devices for neurostimulation, measurement and energy storage.

https://grapheton.com/
Terry Lingren | tlingren@grapheton.com

GreenJay Therapeutics
Conroe, Texas

GreenJay Therapeutics, Inc. (GreenJay) is a clinical-stage pharmaceutical, Texas-based company focused on reformulation of drugs with significant deficiencies. The Company has developed a new formulation of IV busulfan. Current IV formulations of busulfan on the market contain a toxic excipient whereas the new formulation developed by GreenJay does not. This new formulation of IV Busulfan, Bulanta™, may be approved by the FDA without additional preclinical toxicology studies or clinical trials.

http://www.greenjaytherapeutics.com
Michael Redman | mredman@greenjaytherapeutics.com

Hera Biotech
San Antonio, Texas

Hera Biotech, Inc. is a female-led Delaware "C" Corp based in San Antonio, TX that is applying novel advances in biotechnology to address unmet needs in the field of women's health. Hera's vision is to become an industry leader in tissue-based diagnostics for women's health. Hera's lead product is MetriDx™, a novel, non-surgical method for the definitive diagnosis and staging of endometriosis, a highly prevalent and debilitating condition that currently lacks a non-surgical means of diagnosis. Hera raised its oversubscribed seed round and is now launching a $15 million Series A to fund regulatory allowance and commercialization of the test.

http://www.herabiotech.com
Somer Baburek | somer@herabiotech.com

ImmunoGenesis
Houston, Texas

ImmunoGenesis is a clinical stage immuno-oncology biotech company re-envisioning "cold" tumor treatment. Representing more than half of all cancers, cold tumors lack activated T cells or have other immune resistance mechanisms, and current immunotherapies have shown limited to no efficacy in this subtype. ImmunoGenesis' immune therapies are based in the pathology of these cold tumors, transforming them into hot tumors by targeting key mechanisms of immune resistance. The company expects to initiate clinical trials of its lead programs in 2022. The company was founded in 2019 by Dr. Michael A. Curran from MD Anderson Cancer Center.

http://www.immunogenesis.com
James Barlow | james.barlow@immunogenesis.com

InformAI
Houston, Texas

InformAI delivers AI-enabled healthcare informatics solutions that improve quality, safety, and efficiency and enable large dataset synthesis in clinical care. Our platform products solve clinical pain points identified by key opinion leaders, and are deployed in strategic healthcare markets. With a streamlined regulatory process and key advisory team, we develop AI-based medical image diagnostic tools and clinical outcome predictors for physicians, hospitals, and medical imaging/medical device companies. The company has received NSF and CPRIT awards, and is part of the JLABS innovation center in the Texas Medical Center, the world's largest medical provider with 10 million annual patient encounters.

http://informAI.com
Jim Havelka | jcoleman@informai.com

Lexicon Pharmaceuticals
The Woodlands, Texas

Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.

https://www.lexpharma.com
Jeff Wade | jwade@lexpharma.com

Liberate Medical
Crestwood, Kentucky

Liberate Medical is a clinical-stage medical device company focused on respiratory disease. Its lead product, the VentFree Respiratory Muscle Stimulator, reduces the duration of invasive mechanical ventilation by automatically applying non-invasive neuromuscular electrical stimulation to the expiratory muscles in synchrony with mechanical ventilation. This is a large and expensive problem with an estimated potential total addressable market in the US & EU of $2B+. Beyond ventilator weaning, there is significant potential for a home use version of the technology to help patients recover from hospitalization and to assist breathing in patients with COPD.

http://www.liberatemedical.com
Angus McLachlan | angus@liberatemedical.com

Linovasc
Redwood City, California

Linovasc has developed a toroidal balloon catheter device. The device does not "dead-head" the aorta blocking distal blood flow. Not fighting the forces from pulsating blood pressure allows for precise placement with less stress. There isn't a need to inflate the balloon like a truck tire to anchor it in a wet slippery aorta. Our technology is low-cost and competitive with the spherical balloon avoiding the extraordinarily expensive result for a ruptured aorta in terms of death, quality of life, and hospital costs. Typical extended stay is 3 weeks plus the patient's original care needs in a critical care setting.

http://linovasc.com
Bruce Addis | bruce@linovasc.com

Lonza
Basel, Switzerland

At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of 17,000 skilled employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets.

By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases.

https://www.lonza.com
Frank Bugg | frank.bugg@lonza.com

March Biosciences
Houston, Texas

March Biosciences Is a Houston, TX based clinical-stage cell-therapy impacting the most challenging lymphoma and leukemias. The company lead asset is at end-of-Phase I trials T-cell leukemia and lymphoma (T-ALL and TCL). The company has a pipeline of assets designed which build on its current successes in T-ALL and TCL and beyond to impact hematological malignancies more broadly.

http://march.bio/
Sarah Hein | sarah@march.bio

Medly Therapeutics
West Brookfield, Massachusetts

Developed at University Health Network, Canada's largest research hospital, Medly has unrivaled clinical validation showing a 50% reduction in heart failure related hospitalization with a 6X increase in patient capacity. With regulatory clearance as a Class II medical device in Canada, $3M in pre-launch combined revenue and pipeline and a term sheet secured, Medly is raising a $3-5M seed round to launch to expand sales to the US.

https://medly.ai
Tracey Dodenhoff | tracey.dodenhoff@medly.ai

MemoryWell
Washington, D.C.

MemoryWell is a revenue-generating, senior-focused engagement company that uses proprietary algorithm-driven conversational interactions to engage seniors and help Medicare Advantage plans lower costs and increase revenue. We have dismantled the paradigm that “increased payer efficiencies come at the cost of decreased member intimacy and satisfaction”. Every day we help our partners restore humanity in healthcare with a unique, inspiring approach, where everybody wins through our three products: EngageOS, Full-Service Engagements, and Life Stories. Founded by veteran journalist and best-selling author Jay Newton-Small and on-track to generate $2.5MM in 2023 revenues, MemoryWell is seeking $3MM of seed capital.

http://memorywell.com
Jay Newton-Small | jay.newton-small@memorywell.com

Metaclipse Therapeutics
Atlanta, Georgia

Metaclipse Therapeutics is developing novel immunotherapies for solid tumors and vaccines for infectious disease. Our technology platform comprises combining particulate antigen formulations with our proprietary membrane-bound cytokine and immunostimulatory protein adjuvants. Our Membrex® autologous immunotherapy combines neoantigens and tumor-associated antigens from the patient's tumor with our proprietary protein adjuvants. Our first-in-human clinical trial Membrex® product in triple negative breast cancer is on track to begin in 2022. Our VaxRexTM vaccine products are designed to elicit potent humoral and cellular immunity and provide superior protection for the elderly and immuno-compromised individuals.

http://www.metaclipse.com
Michael Coleman | mcoleman@metaclipse.com

MRG Health-SmartCare360
Houston, Texas

The problems we address are patient access to care & adoption of virtual care management solutions, technical literacy issues, language barriers, staffing issues, fragmented technologies, and interoperability issues are the primary focus of our platform. We are providing a complete end to end EMR integrated determinants of health & disease specific virtual care management SAAS and clinical call center services via a dual payment model specific ie: Fee for service CPT code and Value based managed care contracting payment model platform that includes Telehealth, Remote patient monitoring, Remote therapeutic monitoring, Chronic care management, Transitional care management and personalized disease specific health & wellness programs.

https://mrghealth.com/
Kyle Christopher | Kyle@MRGhealth.com

MusiQ Bio
Colleyville, Texas

MusiQ Bio (MusiQ) is a biotechnology company with a mission to develop a first in class platform for delivery of diverse therapeutic payloads to solve the largest challenges facing drug delivery. Based on conventional, FDA approved ultrasound contrast agents (microbubbles), our platform provides non-immunogenic, targeted delivery of diverse therapies directly to the cytoplasm of targeted cells. The platform is broad and includes delivery to any cell of interest that contains an appropriate target; the therapeutic payload includes RNAs, DNAs, proteins and small molecules. MusiQ is developing a broad yet selective platform for specific delivery of diverse therapies to targeted cells.

Jacques Lux | Jacques.Lux@UTSouthwestern.edu

NKILT Therapeutics
Springfield, New Jersey

NKILT Therapeutics is a new cell therapy biotech coming out of stealth mode, that is developing a novel approach of engineering Natural Killer (NK) cells to directly target leukemias and solid tumors. Our initial platform, NKILTer, is a novel Chimeric ILT-Receptor (CIR), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers). Our initial armored CIR-NK cells will be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor's defense mechanisms. The first indication will be Acute Myeloid Leukemia (AML) as a proof of concept, expanding rapidly to a basket of solid tumors such as Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and more HLA-G+ tumors.

http://www.nkilt.com
Raphaël OGNAR | raphael.ognar@nkilt.com

Noninvasix

Galveston, Texas

Noninvasix will be the first company to non-invasively monitor central venous oxygenation (ScvO2, oxygen concentration in veins), a key indicator of the progression of sepsis to septic shock. By non-invasively measuring ScvO2, LIVOx™ Central Venous Oxygenation Monitor can detect the onset of septic shock sooner and safer than invasive catheters to enable timely intervention and personalized resuscitation with the promise of reduced costs and improved outcomes. Future developments, enhancements, and evidence will expand the use and clinical impact of the technology in other indications and settings.

http://www.noninvasix.com
David Giarracco | dgiarracco@noninvasix.com

NoviRad

Houston, Texas

NoviRad, Inc. is a seed-stage Medtech startup developing medical device solutions for interventional radiology and surgery. NoviRad's first medical device, the NoviDrain, consists of a novel dual-lumen catheter coupled to a programmable, sensor-driven electromechanical pump system. The NoviDrain addresses the biggest problem with traditional pigtail drainage catheters - clogging. The NoviDrain leads to a much faster resolution of fluid collections in the body by 1) applying active suction and 2) automating the catheter's flushing to clear the lumen and side holes of obstructive debris.

http://www.novirad.com
Matthew Peña | matt@novirad.com

NUA Surgical

Galway, Galway

NUA Surgical is an award-winning Irish start-up dedicated to creating innovative surgical solutions in obstetrics and gynaecology. Our Founding team have over 50 years combined experience and we are working with key opinion leaders around the world to ensure we answer the most pressing unmet clinical needs. Our patented disposable C-Section Retractor is designed to improve the ergonomics of the surgery and reduce the risk of surgical complications, ultimately making C-Sections a safer surgery.

https://nuasurgical.com/
Barry McCann | barry@nuasurgical.com

Olera

Edinburg, Texas

Caring for a loved one can be incredibly challenging and take a toll on caregivers' physical and psychological health. This toll, in part, is due to the complexities associated with navigating the numerous caregiving responsibilities and senior care services involved in the care of the elderly. Olera is currently developing a commercially viable digital platform that virtually connects caregivers to information designed to increase a caregivers confidence in navigating senior care resources available remotely and in the community. By providing a user with tailored information on senior service providers, the platform helps caregivers find services that best fit their needs.

http://olera.care
Jeswin Vennatt | jeswinvennatt123@tamu.edu

PanTher Therapeutics

Watertown, Massachusetts

While there have been tremendous advances in cancer treatment, critical challenges remain including limited ability of drugs to successfully reach the tumor, short half-life, and low retention rate on site. We have reimagined cancer therapies to tackle these long-standing challenges by leveraging interventional oncology to design superior localized cancer treatments. Panther's proprietary Sagittari™ platform can transform standard of care for these patients by designing customizable products engineered to precisely deliver proven and novel therapies directly onto the tumor to attack cancer at the source.

http://www.panthertx.com
Laura Indolfi | lindolfi@panthertx.com

PONS

Newark, New Jersey

PONS is a compact ultrasound device that can be used by the consumers with an AI-driven cognitive function that autonomously performs the risk assessment of health conditions, smart image processing, with mobile ultrasound device, and reporting the findings to doctors.

https://www.ponstech.co
Ilker Haci | ilker@ponstech.co

Prana Thoracic

Houston, Texas

Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for the detection and intervention of early-stage lung cancer. Prana is developing the first minimally invasive, tissue-sparing device for early interception of suspicious pulmonary nodules. Prana is a spin-out of the Johnson & Johnson MedTech Center for Device Innovation.

http://www.pranathoracic.com
Joanna Nathan | joanna@pranathoracic.com

Pulmotect

Houston, Texas

PUL-042 is a patent protected, clinical-stage therapeutic to treat and prevent respiratory infections. It induces the innate immune system in the lung to provide immediate protection from a wide range of inhaled pathogens. The technology comes out of MD Anderson Cancer Center and Texas A&M. PUL-042 has completed three Phase 1/2a and two Phase 2 clinical trials demonstrating safety and antiviral activity. We are positioned to start two additional Phase 2 trials in cancer patients where the market opportunity is greater than $1B. PUL-042 has a myriad of blockbuster potential applications beyond cancer, including COPD, asthma, viral pandemics, and biodefense.

http://www.pulmotect.com
Brenton Scott | bscott@pulmotect.com

Reglagene

Tucson, Arizona

Reglagene is an oncology therapeutics company developing a breakthrough therapy for the safe and effective treatment of brain cancers. Reglagene utilized well validated principles for the creation of brain penetrant therapies to design, manufacture, and test over 800 prototypes. We identified an orally administered, safe, potent, brain penetrant cancer medicine. This therapy works by targeting a protein known as tubulin, the number one clinically validated target in the history of cancer therapy. For decades, pharmaceutical scientists have worked without success to create safe and effective tubulin-targeting therapies that penetrate the brain. Reglagene's achievement of this goal sets us apart.

http://www.reglagene.com
Richard Austin | austin@reglagene.com

Rhythio Medical

Cypress, Texas

Arrhythmias, or irregular heartbeats, are closely correlated with the #1 natural cause of death in the United States, but the only solutions available on the market are treatments such as pacemakers, ICDs, and ablation, which all have their own flaws. Rhythio Medical is developing the first preventative solution for arrhythmias, so that patients at high risk of a life-threatening event might avoid some of these flawed treatments. Our technology is a gel, called the "injectable wire" which can work in conjunction with existing technologies to improve natural conduction in the heart and reduce the odds of an irregularity.

https://www.rhythiomedical.com/
Kunal Shah | contact@rhythiomedical.com

RiverWalk Therapeutics

Helotes, Texas

Riverwalk Therapeutics is developing small molecules for the treatment of metastatic triple negative breast cancer (TNBC) and several other cancers. Late-stage TNBC patients have only a 12% chance of survival and very limited treatment options. We are developing inhibitors that target adenosine-mediated signaling pathways shown to be directly responsible for tumor growth stimulation and immune suppression. These molecules have been shown, in multiple TNBC mouse models, to inhibit primary/metastatic tumors and prevent suppression of the patient's anti-cancer immunity. These drugs will provide a much-needed clinical treatment option for metastatic TNBC patients that have exhausted all other lines of treatment.

http://www.riverwalktherapeutics.com
Johanna Webb | webbj@riverwalktherapeutics.com

Solenic Medical

College Station, Texas

Solenic leverages the unique properties of alternating magnetic fields (AMF) generated by external transducers to eradicate biofilm on the surface of metallic implants. This non-intrusive, non-contact treatment addresses a major complication frequently associated with various surgeries such as knee and hip replacements, orthopedic trauma cases and dental implants. The technology such as knee and hip replacements, orthopedic trauma cases and dental implants. The technology is particularly important and timely given the rise in the aging population and the rapid increase in the number of orthopedic procedures being performed every year. Designated a Breakthrough Device by the U.S. FDA, it has the potential to completely replace the very expensive and risky two-step revision surgical procedure.

http://www.solenic.com
James Lancaster | james.lancaster@solenic.com

Steradian Technologies

Houston, Texas

Developed at Johnson & Johnson's MedTech Center of Device Innovation, Steradian Technologies has invented the first noninvasive, fully-portable infectious disease diagnostic that costs the price of a latte. The RUMI uses novel photon-based detection to collect and diagnose infectious diseases in breath within 30-seconds. The device will be the first human bio-aerosol specimen collector to convert breath into a fully sterile liquid sample, allowing for many applications in direct disease detection. The company has won and received grants from the Bill and Melinda Gates Foundation, Johnson & Johnson, and XPRIZE.

http://www.steradian-tech.com

Asma Mirza | asma@steradian-tech.com

Tachyon Therapeutics

Houston, Texas

Tachyon Therapeutics was founded with the goal to discover and develop first-in-class cancer drugs that target unexplored mechanisms of tumorigenesis. Tachyon's lead compound is TACH101, a first-in-class inhibitor of KDM4 histone demethylase. KDM4 is an epigenetic regulator that controls critical translational processes of gene expressions linked to cell maintenance and function. A broad array of nonclinical models, including organoid, xenograft and patient-derived models of several cancer types has shown consistent efficacy in inhibiting tumor growth. Recently, FDA approved the IND to initiate a first-in-human Phase 1 clinical trial, which is anticipated to commence at the end of 2022. Currently there are no other KDM4 inhibitors in clinical development.

http://www.tachyontx.com

Frank Perabo | fperabo@tachyontx.com

TeVido BioDevices

Austin, Texas

TeVido BioDevices, a Regenerative Medicine company, makes life changing skin cell transplants readily available. It's commercially available TruPigment™ product is used to restore lost skin color and to repair wounds, including burns. TeVido prepares a patient's own living skin cells in an FDA registered Tissue Establishment and provides it to the physician for application. TeVido's serviceable market in the U.S. is estimated to be ~ $4B. TeVido is capital efficient; this opportunity is significantly de-risked and primed for growth.

https://tevidobiodevices.com/

Laura Bosworth | bosworth@tevidobiodevices.com

TYBR Health

Houston, Texas

TYBR Health makes a non-invasive naturally derived hydrogel spray to protect tissues from internal scarring after surgery. Our spray can eliminate the most common adverse side effect of orthopedic surgery—scarring—and therefore prevent lengthy painful rehab programs & restore movement for over 1.8m Americans who undergo tendon or joint surgeries each year.

http://www.tybrhealth.com

Tim Keane | tkeane@tybrhealth.com

Visura

Bloomington, Minnesota

Visura is a medical device company dedicated to delivering state-of-the art visualization solutions to improve the quality of transesophageal echo intubations. Visura has developed the TEECAD System, the world's first FDA-cleared, disposable camera that seamlessly connects to a TEE probe, providing physicians real-time visualization for more efficient and effective probe placement for their patients potentially undergoing structural heart interventions or diagnosis.

https://www.visuratechnologies.com/
Christine Horton | christine.horton@visuratechnologies.com

Vivifi Medical

Houston, Texas

500M+ men affected by BPH globally. All current treatment options only provide temporary symptomatic relief at the cost of relief-duration, pain and sexual functions. Vivifi's technology enables a superior version of procedure that is clinically proven to reverse BPH while simultaneously boosting testosterone levels and restoring pre-existing sexual dysfunctions – a penetrable market of $20B+

http://www.vivifimedical.com
Tushar Sharma | tushar@vivifimedical.com

Voythos

Houston, Texas

Physicians are spending over half their time on administrative tasks, resulting in severe burnout, poor clinical care, and financial loss. As a team of physicians, technologists, and healthcare IT professionals, we know this pain firsthand. Voythos is a mobile physician companion designed to simplify all aspects of patient charting and automate care workflows, significantly improving outcomes and reducing physician burnout - all while allowing for clinics and hospitals to keep their legacy EMR systems.

http://voythos.io
Sophia Khan | skmakoid@voythos-ai.com